

Mathias Vormehr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1335400/publications.pdf>

Version: 2024-02-01

27
papers

8,459
citations

471371

17
h-index

580701

25
g-index

37
all docs

37
docs citations

37
times ranked

13207
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	13.7	1,806
2	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 2020, 586, 594-599.	13.7	1,520
3	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	13.7	1,243
4	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 2015, 520, 692-696.	13.7	1,030
5	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 2021, 595, 572-577.	13.7	583
6	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	13.7	526
7	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	13.7	494
8	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	13.5	287
9	mRNA therapeutics in cancer immunotherapy. Molecular Cancer, 2021, 20, 69.	7.9	168
10	Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clinical Cancer Research, 2016, 22, 1885-1896.	3.2	128
11	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. Frontiers in Oncology, 2020, 10, 1195.	1.3	94
12	Mutanome directed cancer immunotherapy. Current Opinion in Immunology, 2016, 39, 14-22.	2.4	55
13	Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. Annual Review of Medicine, 2019, 70, 395-407.	5.0	54
14	Steatohepatitis Impairs T-cellâ€Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	0.6	46
15	A liposomal RNA vaccine inducing neoantigen-specific CD4 ⁺ T cells augments the antitumor activity of local radiotherapy in mice. OncoImmunology, 2020, 9, 1771925.	2.1	32
16	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. Journal of Immunology Research, 2015, 2015, 1-6.	0.9	27
17	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. OncoImmunology, 2019, 8, e1601480.	2.1	18
18	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. OncoImmunology, 2020, 9, 1758004.	2.1	17

#	ARTICLE	IF	CITATIONS
19	A non-functional neoepitope specific CD8 ⁺ T-cell response induced by tumor derived antigen exposure <i>in vivo</i> . <i>Oncolmunology</i> , 2019, 8, 1553478.	2.1	16
20	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. <i>Methods in Molecular Biology</i> , 2017, 1499, 223-236.	0.4	9
21	Personalized Neo-Epitope Vaccines for Cancer Treatment. <i>Recent Results in Cancer Research</i> , 2020, 214, 153-167.	1.8	9
22	Abstract A110: Mutant MHC class II epitopes drive therapeutic immune responses to cancer. , 2016, , .		3
23	A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. <i>BMC Cancer</i> , 2019, 19, 914.	1.1	1
24	561â€¦DuoBody®-PD-L1-4â€“1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4â€“1BB co-stimulation. , 2020, , .		1
25	Abstract 5012: Establishment of a transplantable, NY-BR-1 expressing breast cancer model in HLA-transgenic mice. , 2015, , .		0
26	Abstract CT022: IVACÂ® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma. , 2016, , .		0
27	Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms. , 2016, , .		0